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The replication of viruses depends on the cell cycle status of the
infected cells. Viruses have evolved functions that alleviate restric-
tions imposed on their replication by the host. Vpr, an accessory
factor of primate lentiviruses, arrests cells at the DNA damage
checkpoint in G2 phase of the cell cycle, but the mechanism
underlying this effect has remained elusive. Here we report that
Vpr proteins of both the human (HIV-1) and the distantly related
simian (SIVmac) immunodeficiency viruses specifically associate
with a protein complex comprising subunits of E3 ubiquitin ligase
assembled on Cullin-4 scaffold (Cul4–DDB1[VprBP]). We show that
Vpr binding to Cul4–DDB1[VprBP] leads to increased neddylation
and elevated intrinsic ubiquitin ligase activity of this E3. This effect
is mediated through the VprBP subunit of the complex, which
recently has been suggested to function as a substrate receptor for
Cul4. We also demonstrate that VprBP regulates G1 phase and is
essential for the completion of DNA replication in S phase. Fur-
thermore, the ability of Vpr to arrest cells in G2 phase correlates
with its ability to interact with Cul4–DDB1[VprBP] E3 complex. Our
studies identify the Cul4–DDB1[VprBP] E3 ubiquitin ligase complex
as the downstream effector of lentiviral Vpr for the induction of
cell cycle arrest in G2 phase and suggest that Vpr may use this
complex to perturb other aspects of the cell cycle and DNA
metabolism in infected cells.
Cullin 4
The replication of HIV and other lentiviruses is restricted tosome degree by the cell cycle status of the target cells.
Although lentiviruses can infect nondividing cells, and thus
establish stable reservoirs in CD4 T cells and terminally differ-
entiated macrophages, they fail to replicate in quiescent cells (1).
The observation that cells in G2 phase support lentivirus repli-
cation more efficiently than those in G1 phase further illustrates
how the cell cycle status influences primate lentiviruses (2). HIV
replication is also constrained by host cell mechanisms that
detect and repair damaged DNA. For instance, the reverse-
transcribed retroviral genomes are targeted for degradation by
DNA repair proteins XPB and XPD (3), and the final steps of
the integration of the reverse-transcribed retroviral genome into
chromosomal DNA are thought to be catalyzed by DNA repair
enzymes of the host cell (4). Viruses have evolved functions that
partially alleviate various restrictions imposed on their replica-
tion by the host. In particular, accessory proteins of primate
lentiviruses, such as Vpr, Vif, Nef, and Vpu, execute several such
functions (5).
Vpr accessory proteins are multifunctional regulators located
in the nuclei of the infected cells (6). Although Vpr is not
required for lentivirus replication in cultured cells, its conser-
vation in HIV-1, HIV-2, and simian immunodeficiency viruses
(SIV) indicates that a strong selective pressure to preserve these
proteins must operate in vivo. Indeed, Vpr was shown to
accelerate progression to AIDS in rhesus macaques infected
with SIV in the absence of a closely related SIV Vpx protein (7).
How Vpr contributes to lentiviral pathogenesis is still under
intense investigation. One conserved function of lentiviral Vpr
is its ability to arrest the infected cells in the G2 phase of the cell
cycle (8, 9). Vpr was also reported to suppress HIV-1 mutation
rate, and this effect was correlated with its interaction with
host-derived uracil DNA glycosylase, UNG2 (10). This enzyme
is involved in the base excision repair pathway that specifically
removes uracil from DNA (11). A recent study suggested that
Vpr directs degradation of UNG2 to stabilize HIV reverse-
transcription products (12). Finally, Vpr has been implicated as
one of the factors that facilitates infection of terminally differ-
entiated macrophages possibly by promoting entry of the HIV
preintegration complex into the nucleus (13).
Themost extensively studied Vpr function is its ability to arrest
cycling cells in the G2 phase of the cell cycle (8, 9). One candidate
mechanism for this function is suggested by the observation that
Vpr activates the ataxia telengiectasia and Rad3-related (ATR)
protein kinase (14). ATR triggers checkpoint signaling on geno-
toxic stress to stop the progression of the cell cycle until the
damaged DNA is repaired (15). Recent evidence suggests that
Vpr leads to ATR activation by interfering with the DNA
replication machinery of the infected cell (16) and implicates
Cullin 4 ubiquitin ligase containing VprBP/DCAF1 as poten-
tially important for this effect (17, 18). It should be pointed out,
however, that Vpr was also reported to interact with signaling
molecules downstream of ATR, such as 14–3-3 proteins and
Cdc25C, raising the possibility that additional mechanisms may
be usurped by the viral protein to perturb the progression of the
cell cycle (19–21).
The 3D structure of HIV-1 Vpr implies that it functions as an
adaptor protein (22). Hence, we used a proteomic approach to
identify the key cellular proteins that Vpr binds to subvert DNA
replication and cell cycle regulation. Here we show that Vpr
binds and deregulates an unstudied Cul4 E3 ubiquitin ligase
complex containing damaged DNA binding protein 1 (DDB1),
WD40-repeat containing VprBP, and DDA1 subunits. The
DDA1–DDB1–VprBP–Vpr complex we purified is probably
the most abundant Vpr-containing protein complex in the cell.
The previously characterized Cul4 ligase complexes control
DNA replication and DNA repair through ubiquitination of key
substrates in these pathways (23–28). The Cul4 complex targeted
by Vpr appears to regulate the G1 phase of the cell cycle and is
essential for completion of DNA replication in S phase. We
further demonstrate that, through the interaction with this Cul4
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complex, Vpr arrests cells in the G2 phase. Together our studies
identify the immediate downstream effector of Vpr for G2 cell
cycle arrest and suggest additional scenarios for howVprmay use
this complex to perturb other aspects of the cell cycle and DNA
metabolism in infected cells.
Results
HIV-1 and SIV Vpr Proteins Bind a Common Set of Proteins.To address
the molecular mechanisms used by the lentiviral Vpr proteins,
we purified protein complexes containing HIV-1 Vpr or its
orthologue encoded by the pathogenic SIVmac 239 strain. Vpr
proteins were tagged at their N-termini with FLAG and HA
epitopes in tandem and expressed stably in U937 monocytes or
transiently in human embryonic kidney 293 T (HEK293T) cells.
Next, Vpr and their associated proteins were purified from
detergent extracts by sequential immunoprecipitations with
-HA- and then -FLAG-epitope antibodies, followed each
time by elution with the respective peptide epitope.
The immunoprecipitates were analyzed by Multidimensional
Protein Identification Technology (MudPIT). MudPIT is a
combination of chromatographic and mass spectrometric pro-
cedures that allow unbiased and sensitive identification of pro-
teins in complex mixtures. Three relatively abundant polypep-
tides, DDB1, DDA1, and VprBP, that were specifically
associated with Vpr proteins from both HIV-1 and SIVmac,
which are two distantly related primate lentiviruses (29), in both
U937 and HEK293T cells and absent in purifications from
negative control cells were thus identified (SI Table 1). The
conservation of these interactions suggested that they are im-
portant mediators of a common Vpr function. Therefore, we
focused our studies on these proteins.
DDA1, DDB1, and VprBP Form a Ternary Complex That Vpr Binds. The
finding that Vpr binds DDB1, VprBP, and DDA1 linked Vpr to
Cullin-4 RING E3 (Cul4 E3) ubiquitin ligase complexes. DDB1
is an obligatory subunit of Cul4 E3 ligases (30). These enzymes
regulate DNA repair and replication and cell cycle progression
through ubiquitination of key substrates in these processes.
VprBP, a known HIV-1 Vpr binding protein (31), and DDA1
have been found recently to bind DDB1 (26); however, their
normal functions remain unknown. Therefore, to gain further
insights into Vpr interactions with these polypeptides, we char-
acterized Vpr association with VprBP, DDB1, and DDA1.
The observations that VprBP and DDA1, as well as DDB1, all
copurified with Vpr, and that they were recovered at similar
relative abundance based on relative spectral counts (see SI
Table 1), suggested that they form a ternary complex, which is
then targeted by Vpr. To address these possibilities, FLAG-
tagged VprBP, DDB1, DDA1, and Vpr were individually ex-
pressed in HEK293T cells. Detergent extracts from the trans-
fected and control cells were immunoprecipitated with -FLAG
beads and immune complexes analyzed by immunoblotting. As
shown in Fig. 1A, each protein was capable of associating with
each other (lanes 3–5). Next, the complexes purified via VprBP
and HIV-1 Vpr (lanes 2 and 3) were separated on 10–40%
glycerol gradients by ultracentrifugation. As shown in Fig. 1B,
DDB1 (127 kDa molecular mass), DDA1 (11.8 kDa), and
VprBP (169 kDa) all peaked in fractions 6 and 7, indicating that
they form a ternary complex of 300–400 kDa (Fig. 1B Upper).
Notably, the bulk of the Vpr-bound VprBP, DDB1, and DDA1
cosedimented with similar velocities (Fig. 1B Lower). Their
distributions, however, were shifted toward the bottom of the
gradient, compared with those in the absence of Vpr, suggesting
that the viral protein may recruit additional components to these
complexes. We conclude that VprBP, DDB1, and DDA1 form
a ternary complex, which Vpr binds, and that the viral protein
may modulate interactions between the DDA1–DDB1–VprBP
complex and other factors.
Vpr Elevates Neddylation of Cul4 in Cul4–DDB1[VprBP] E3 Complex.
Surprisingly, although DDB1 functions through participation in
the Cul4 E3 ligase platform (30), our MudPIT analyses detected
only a few Cul4-derived peptides in -Vpr immune complexes.
This observation suggested that Cul4 is not a stoichiometric
subunit of the Vpr complex we purified. To address a link to Cul4
ubiquitin ligase, we further characterized the interaction be-
tween Vpr and Cul4. Myc-tagged Cul4A was coexpressed to-
gether with VprBP and/or HIV-1 Vpr by transient transfection
in HEK293T cells. In some experiments, Vpr, or VprBP, were
FLAG-tagged to facilitate their immunoprecipitation. -FLAG
immune complexes prepared from transfected cells were ana-
lyzed by immunoblotting for Cul4. As shown in Fig. 2A, Cul4 was
found in FLAG–VprBP immune complexes, thus confirming
that VprBP participates in Cul4 E3 ligase complex (lanes 6 and
7) (26). Significantly, Cul4 was also found in FLAG–Vpr immune
complexes, but only when VprBP was also ectopically expressed,
thereby confirming that Vpr association with Cul4 is bridged by
VprBP (compare lanes 3 and 2).
The ubiquitin ligase activity of cullin complexes is regulated by
cycles of Nedd8 moiety attachment to the cullin scaffold and its
removal (32). The neddylated forms of cullins migrate slower
than their unmodified forms during SDS/PAGE electrophoresis.
Strikingly, ectopic expression of Vpr and VprBP together elic-
ited a slower migrating Cul4A species readily detectable in
detergent extracts prepared from the transfected cells (Fig. 2A
top gels, lanes 3, 4, 7, 12, and 13). This Cul4 species was less
pronounced in control experiments where Vpr, or VprBP, were
expressed separately (lanes 2, 6, 8, 10, and 11). Immunoprecipi-
tation experiments revealed that both Cul4A forms were asso-
ciated with VprBP (Fig. 2A, middle gels, lane 7) and with Vpr,
but only when VprBP was also ectopically expressed (compare
lanes 2 and 3). Immunoblotting of the immune complexes for
Nedd8 confirmed that the slower migrating Cul4A species was
indeed the neddylated form (Fig. 2A, bottom gels, lanes 3 and 7).
The data described above demonstrated that Vpr can increase
Cul4 neddylation through its interaction with VprBP, but they
did not rule out that Vpr causes generalized neddylation of Cul4
present in other Cul4–DDB1 complexes. To address this latter
possibility, we tested the effect of Vpr on the Cul4A component
of the previously well characterized Cul4 E3 complex that
contains DDB2 subunit instead of VprBP and mediates repair of
Fig. 1. Vpr binds DDA1–DDB1–VprBP complex. (A) Biochemical interactions
among Vpr, VprBP, DDB1, and DDA1. Detergent extracts from HEK293T cells
transiently expressing FLAG-tagged HIV-1 Vpr (lane 2), VprBP (lane 3), DDB1
(lane 4), or DDA1 (lane 5) subunits were immunoprecipitated (IP) with -FLAG
beads, and immunoprecipitates were analyzed by immunoblotting for VprBP,
DDB1, DDA1, Vpr, and COP9 signalosome subunits CSN3 and CSN8. (B) Vpr
binds the DDA1–DDB1–VprBP complex. FLAG-VprBP (Upper) and FLAG-Vpr
(Lower) containing complexes were sedimented through 10–40% glycerol
gradients. Aliquots of fractions collected from the tops of the gradients were
immunoblotted for the indicated proteins.
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damaged DNA (Cul4-DDN1[DDB2]) (23). As shown in Fig. 2A,
Vpr did not induce detectable neddylation of Cul4A associated
with DDB2, regardless of whether VprBP was also ectopically
expressed (middle gels, lanes 10 and 12). We conclude that Vpr
specifically binds the Cul4–DDB1[VprBP] complex and in-
creases the levels of neddylated Cul4A in that complex only.
Vpr Elevates Intrinsic Ubiquitin Ligase Activity of Cul4–DDB1[VprBP]
E3. The increase in Cul4 neddylation suggested that Vpr may
modulate the catalytic activity of the Cul4–DDB1[VprBP] E3
ubiquitin ligase complex. To address this possibility we assem-
bled the Cul4–DDB1[VprBP] complexes with or without HIV-1
Vpr, purified them via their FLAG-VprBP subunits, and com-
pared their intrinsic ubiquitin ligase activities in an in vitro assay.
Because the identity of the relevant substrates of these E3
complexes is not yet known, we measured their abilities to
autoubiquitinate Cul4 (23). As shown in Fig. 2B, the Cul4–
DDB1[VprBP] E3 complex assembled with HIV-1 Vpr pos-
sessed a robust autoubiquitinating activity, and this activity
required exogeneous E2 (lane 5). In contrast, the catalytic
activity of the E3 complex that did not contain Vpr was relatively
low (lane 4). We conclude that Vpr stimulates intrinsic ubiquitin
ligase activity of the Cul4–DDB1[VprBP] E3 complex.
VprBP Is Required for the Ability of Vpr to Accumulate Cells in G2. As
aforementioned, Cul4 E3 ubiquitin ligases are thought to control
DNA replication and progression of the cell cycle (23–28). We
hypothesized that Vpr usurps VprBP and the Cul4 –
DDB1[VprBP] E3 complex to perturb these processes. There-
fore, experiments were performed to characterize the normal
function of VprBP.
Initial f luorescence microscopy and laser scanning cytometry
experiments revealed that VprBP is located primarily in the
nucleus and is expressed throughout the cell cycle (SI Fig. 5). To
gain insight into the normal function of VprBP, we knocked
down its expression by using RNA interference (RNAi). Human
osteosarcoma U2OS cells were transduced with TRIP lentiviral
vectors expressing short hairpin RNAs (shRNA) specific for
VprBP or a control shRNA specific for DOCK2 guanine nucle-
otide exchange factor, which is expressed only in hematopoietic
cells (33). Three days later, the transduced cells were infected
again, this time with a bicistronic TEIG lentiviral vector express-
ing HIV-1 Vpr and GFP or with a control empty TEIG vector.
After 3 more days, the transduced populations were analyzed for
VprBP expression to confirm that VprBP levels were depleted
and for DNA content to evaluate the effect of Vpr expression on
the cell cycle. Immunoblot analysis revealed that VprBP expres-
sion levels were greatly reduced by RNAi (Fig. 3D). Analysis of
DNA profiles of the cell populations demonstrated that Vpr
arrested the control DOCK2 knockdown cells in G2 (Fig. 3A). In
contrast, the cell cycle profiles of VprBP-depleted cells were
virtually identical regardless of whether Vpr was expressed in
these cells. These data suggested that VprBP-depleted cells are
resistant to the effect of Vpr.
VprBP-Depleted Cells Arrest in G1 and G2 Phases.Wenext studied the
effect of VprBP knockdown on progression of the cell cycle in
U2OS cells. VprBP-depleted and control DOCK2 knockdown
cells were cultured for 1 h in the presence of BrdU to label
S-phase cells. Next, the cells were cultured without BrdU for12
h to allow time for progression of the BrdU-labeled cells through
the S and G2 phases and mitosis. Subsequently, BrdU incorpo-
ration and DNA content in the cell populations were quantified
by flow cytometry. Several aberrations in cell cycle profiles of the
VprBP-depleted cells were revealed by these analyses. Strikingly,
VprBP depletion led to a dramatic accumulation of cells in the
G1 phase. As shown in Fig. 3B Lower, 65% of VprBP-depleted
cells were found in G1 compared with 43% in the control
population. Consistently, only a few VprBP-depleted cells ap-
peared to replicate their DNA, as seen from a relatively low
frequency of the BrdU-positive cells (11% vs. 45% in the control
population). Moreover, an abnormally high proportion of
VprBP-depleted cells was found in the G2 phase (23% vs. 12%).
Notably, relatively few of the VprBP-depleted cells that were in
late S or G2 at the time of BrdU labeling divided within the
following 12-h period, compared with nearly all such cells in the
control population. Overall, these data reveal that the majority
of the VprBP-depleted cells were arrested in the G1 and G2
phases, thus suggesting the activation of DNA damage check-
points. Additionally, the fact that VprBP-depleted U2OS cells
were not cycling explains why Vpr was unable to cause their
accumulation in G2 (Fig. 3A).
VprBP Depletion Leads to the Activation of DNA Damage Response.
To assess whether VprBP depletion led to the activation of DNA
damage checkpoints, we characterized the expression of serine
139-phosphorylated histone H2A.X variant (-H2A.X). H2A.X
is phosphorylated early on in response to DNA damage and is
involved in the recruitment of repair proteins to the vicinity of
DNA lesions (34). As shown in Fig. 3C, levels of -H2A.X
expression were elevated in the G2-phase VprBP-depleted cells
compared with control cells. This observation supports the
notion that a subpopulation of VprBP-depleted U2OS cells is
arrested in the G2 phase at the DNA damage checkpoint.
Next, we analyzed expression of key checkpoint proteins and
cell cycle regulators by immunoblotting (Fig. 3D). Notably, the
steady-state levels of p53 and p21 cyclin-dependent kinase
inhibitor, which mediate p53-dependent DNA damage check-
point (35), were both increased in VprBP-depleted cells. The
levels of S-phase cyclin A and of cyclin B1 were relatively low,
in agreement with a low frequency of S-phase cells (see Fig. 3
B–D). The expression levels of cdc6 and geminin, which control
replication complex assembly and replication licensing (36),
were also relatively low, consistent with low expression levels of
these proteins in G1 cells. Together our observations provide
evidence that depletion of VprBP leads to the activation of
cellular response to DNA damage and arrest of the cells in the
G1 and G2 phases at DNA damage checkpoints.
Fig. 2. Vpr elevates neddylation and intrinsic ubiquitin-ligase activity of the
Cul4–DDB1[VprBP] E3 complex. (A) Vpr binds to and specifically elevates
neddylation of Cul4A associated with VprBP. Myc-tagged Cullin 4A (m-Cul4)
was coexpressed with Vpr, VprBP, and DDB2, in various combinations, in
HEK293T cells. FLAG-tagged (f) versions of these proteins were used in some
experiments to facilitate their immunoprecipitation. m-Cul4A (arrow) and its
neddylated form (*) were detected in detergent extracts (Extr) and -FLAG
immune complexes (IP) by immunoblotting with -myc and -Nedd8 antibod-
ies, respectively. (B) Vpr stimulates intrinsic ubiquitin ligase activity of the
Cul4–DDB1[VprBP] E3 complex.m-Cul4–DDB1[VprBP] complexes were assem-
bled with or without Vpr in HEK293T cells, purified via their FLAG-VprBP
subunits, and incubated with E1, ubiquitin, and/or E2 as indicated. Cul4A and
its ubiquitinated forms were detected by immunoblotting for Cul4.
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HIV-1 Vpr Arrests Cell Cycle by Interacting with the Cul4–DDB1[VprBP]
E3 Complex. Observations from our genetic and biochemical
studies indicated that VprBP influences the transition from S to
G2 phase probably through modulation of the DNA replication
and/or damage repair processes. Significantly, RNA interference
mediated depletion of the DDA1 and DDB1 subunits of the E3
complex targeted by Vpr also leads to cell cycle perturbations
and activation of DNA damage response (SI Figs. 6 and 7) (28).
This evidence strongly suggested that Vpr arrests cells in the G2
phase through its interaction with the DDA1–DDB1–VprBP
complex and its associated Cul4 E3 ubiquitin ligase. To address
this possibility, a panel of HIV-1 vpr alleles were tested for their
abilities to arrest cells in G2, associate with VprBP and DDB1,
and elevate Cul4A neddylation via VprBP.
U2OS cells were transduced with retroviral MIG vectors
expressing wild-type or mutant HIV-1 Vpr proteins, and their
cell cycle profiles were analyzed 3 days later. As shown in Fig. 4A,
75% of cells transduced with wild-type vpr were arrested in G2.
Notably, Vpr also caused accumulation of cells with 4n DNA
content, suggesting that the viral protein can interfere with
replication licensing (36). Next, we tested two mutations, one
substituting arginine for histidine H71 (H71R) and the other
attaching a tandem FLAG-HA epitope tag to the C terminus of
the Vpr molecule (C-tag). Both mutations disrupted the ability
of Vpr to arrest cells in the G2 phase, in agreement with a
previous report (37). Notably, neither of the two proteins was
able to associate with VprBP or DDB1, or to increase the levels
of neddylated Cul4A (Fig. 4 B and C). Substitution of proline for
alanine A30 (A30P) slightly diminished the ability of Vpr to
arrest cells in G2 and also slightly decreased Vpr binding to
VprBP and DDB1 and Cul4 neddylation. In contrast, no such
effects were seen with two other mutations (W54R and I63G)
that did not affect the ability of Vpr to arrest cells in G2. Of note,
theW54R substitution was found to elevate the association of the
viral protein with VprBP and DDB1, but did not elevate Cul4
neddylation above the level seen with wild-type Vpr. Thus, the
binding of Vpr to VprBP probably is not sufficient to increase
Cul4 neddylation, and some additional Vpr function is likely
required for this effect. These data provide genetic and bio-
chemical evidence in support of a model in which Vpr arrests
cells in G2 by targeting the Cul4–DDB1[VprBP] E3 ubiquitin
ligase.
Discussion
In a search for downstream effectors of lentiviral Vpr, we
purified an abundant Vpr-associated protein complex and iden-
tified its components as subunits of a specific ubiquitin ligase
complex assembled on Cul4 scaffold (Cul4–DDB1[VprBP]).
The VprBP subunit of this complex contains canonical WD40/
WDXR motifs, similar to known Cul4 substrate receptors, such
as DDB2, CSA, and Cdt2, which use these motifs to dock to
DDB1 (23, 38). DDB1, in turn, connects them to Cul4. Thus, by
analogy to these polypeptides, VprBP probably functions as a
substrate receptor for Cul4 (17, 26, 38). Importantly, our data
show that Vpr positively regulates the ubiquitin ligase activity of
this specific E3 complex probably by elevating neddylation of
Cul4. Covalent conjugation of a Nedd8 moiety to cullin is
thought to mediate the recruitment of the E2-conjugating en-
zyme for the ubiquitin transfer reaction, thereby up-regulating
ubiquitin ligase activity of the E3 complex (23, 39, 40). Regarding
the mechanism that underlies the increased neddylation of
Vpr-associated Cul4, Vpr could promote Nedd8 ligation to Cul4
or stabilize the neddylated Cul4 by inhibiting Nedd8 deconju-
gation by COP9 signalosome or another isopeptidase (40). Of
note, we observed that COP9 subunits were undetectable in the
E3 complexes associated with Vpr, but present in those assem-
bled in the absence of Vpr expression (see Fig. 1, lanes 2 and 3;
and data not shown). This evidence suggests that Vpr up-
regulates the catalytic activity of Cul4–DDB1[VprBP] by inter-
fering with Nedd8 deconjugation by COP9.
Two lines of evidence suggest that Vpr usurps the Cul4–
DDB1[VprBP] E3 to arrest cells in the G2 phase. First, our data
link VprBP and its associated Cul4 E3 ubiquitin ligase to the
regulation of DNA replication and the cell cycle. Second, we
found that mutant Vpr proteins deficient for binding the Cul4–
DDB1[VprBP] complex and elevating neddylation of its associ-
ated Cul4 are unable to arrest cells in G2. These findings support
a model in which Vpr perturbs the normal function of Cul4–
DDB1[VprBP] E3, and thereby interferes with the completion
Fig. 3. VprBP depletion leads to G1 and G2 phase arrests. (A) The effect of
RNAi to VprBP on the ability of Vpr to arrest cells in G2. U2OS cells expressing
shRNAs to VprBP (Lower) or DOCK2 (Upper) were transduced with a lentiviral
TEIG vector expressing HIV-1 Vpr (Vpr) or a control empty vector (Vector).
Three days later, the cells were stained with PI, and the DNA content was
analyzed by flow cytometry. (B) VprBP-depleted cells arrest in G1 and G2.
VprBP-depleted (Lower) and control cell populations (Upper) were labeled
with BrdU for 1 h. BrdU incorporation and DNA content were analyzed by flow
cytometry either immediately after BrdU labeling or after 6 and 12 h chase.
Bivariant distributions of BrdU incorporation and DNA content are shown. The
percent fractions of cells in the G1 (Lower Left), S (Upper), and G2 (Lower
Right) phases are indicated. (C) Histone -H2A.X and cyclin A expression in
VprBP-depleted (VprBP) and control cells (vector) were revealed by indirect
fluorescence. Cells were counterstained with DAPI, and fluorescent signals
were imaged with an iCys laser scanning cytometer. Histograms of DNA
content and bivariate distributions of -H2A.X or cyclin A fluorescence versus
DNA content are shown. (D) Levels of cyclins, checkpoint, and replication
licensing proteins in lysates of VprBP-depleted and control cells were analyzed
by immunoblotting with antibodies to the indicated proteins. Splicing factor
2 (SF2) was used as a loading control. The asterisk indicates a band reacting
nonspecifically with the -VprBP IgG. Lanes 1 and 3 contain 3-fold dilutions of
the amounts loaded in lanes 2 and 4, respectively.
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of DNA replication, which leads to the activation of DNA
damage checkpoint and cell cycle arrest in G2 phase.
Available evidence suggests three not exclusive scenarios for
how Vpr may interfere with the normal function of the Cul4–
DDB1[VprBP] E3 ubiquitin ligase. First, our finding that Vpr
specifically stimulates catalytic activity of the Cul4 –
DDB1[VprBP] E3 implies that the viral protein may cause
premature ubiquitination of proteins that are natural substrates
of this ubiquitin ligase complex and mediate DNA replication/
repair. However, the ability of Vpr to activate Cul4 is probably
not sufficient to explain how it arrests cells in G2 because we
observed that the Vpx protein, a Vpr orthologue encoded by
HIV-2 and SIVsm viruses, also binds and stimulates neddylation
of Cul4 in the Cul4–DDB1[VprBP] complex, but does not arrest
cells in G2 (data not shown). Second, Vpr may recruit novel
protein substrates that normally are not recruited by VprBP for
ubiquitination by Cul4. This possibility is supported by recent
evidence that Vpr directs ubiquitination of UNG2 and SMUG
and that this involves Cullin 4 (12, 18). However, neither of these
uracil glycosylases is essential for cell cycle progression, and their
depletion does not explain how Vpr arrests cells in G2. Never-
theless, these data set a precedent to suggest that Vpr may direct
inappropriate ubiquitination of a yet unknown replication fac-
tor(s) and thereby lead to G2 arrest. Third, Vpr could disrupt
recruitment and ubiquitination of a physiological Cul4–
DDB1[VprBP] E3 substrate that is involved in DNA replication.
This possibility is consistent with our observation that RNAi-
mediated loss-of-VprBP function leads to G2 arrest. It is con-
ceivable that a combination of two or more of the above effects
leads to the activation of DNA damage checkpoint and triggers
G2 arrest.
How Vpr, by subverting the VprBP-linked Cul4 E3 ubiquitin
ligase, benefits replication of primate lentiviruses is not known,
but can be speculated on given the existing data. Our evidence
firmly links VprBP to the control of G1-phase progression.
Significantly, previous studies established that a certain thresh-
old of cellular activation is needed to support productive lenti-
viral infection. Although quiescent cells in the G0 state are not
permissive, just a partial stimulation that drives them into the G1
phase without triggering proliferation is frequently sufficient to
establish competence for lentiviral replication (41, 42). Because
cells in late G1 are permissive, whereas those in early G1 are not,
the position of cells in the G1 phase probably determines how
efficiently they support viral replication (41). Thus, Vpr could
benefit HIV replication by manipulating progression through
G0/early G1 phase in noncycling cells and/or minimally activated
cells. Such an effect would benefit the virus early in natural
infection, when the levels of immune activation are low and the
majority of the infected cells are thought to be quiescent.
Another possibility is suggested by the observation that the
depletion of VprBP expression levels by RNAi leads to the
activation of the DNA damage checkpoint in G2. This evidence
links VprBP to the control of DNA synthesis and/or repair
processes that are essential for the completion of S phase.
Notably, recent studies have begun to reveal the unexpected
complexity of the interactions between the replicating retroviral
genomes and cellular machineries that repair damaged DNA.
For example, integration of cDNA copies of retrovirus genomes
is thought to be aided by cellular machineries that mediate repair
of damaged DNA (4). However, it appears that enzymes that
normally mediate repair of damaged DNA target the incoming
retroviral nucleic acids to inhibit, rather than promote, the
infection (3, 43). Moreover, retroviral genomes are substrates for
DNA editing enzymes and additional repair reactions (10, 12,
44). It will be important to determine whether the Cul4–
DDB1[VprBP] complex controls any of these processes. Ulti-
mately, the identification of substrate proteins recruited for
ubiquitination by VprBP, both in the absence and presence of
Vpr, should lead to a better understanding of the roles of
Cul4–DDB1[VprBP] E3 in DNA metabolism, cell cycle control,
and lentivirus infection.
Materials and Methods
Expression Vectors and Viruses.HIV-1 NL4–3 and SIVmac 239 vpr
tagged with N-terminal FLAG-HA-AU1 (hfa) epitopes in tan-
dem (45) and other epitope-tagged cDNAs were cloned into
pBABE-puro, pCG,MIG, and TEIG bicistronic vectors express-
ing GFP (46). shRNAs targeting sequences, listed in supporting
information (SI) Text, were subcloned into TRIP lentiviral
vectors (47). MIG and TEIG are modified MSCV and TRIP
vectors containing a polylinker, followed by internal ribosome
entry site element and GFP cassette derived from pCG. VSV-G
pseudotyped viral particles were produced in transiently trans-
fected HEK293T cells, and viral titers to U2OS cells were
determined by flow-cytometry analysis of GFP/CFP expression.
Immunoaffinity Purification of Epitope-Tagged Proteins and MudPIT
Analysis. Protein complexes were purified by two sequential immu-
noprecipitations via the FLAG and HA epitope tags from 7 g to
12 g of U937 cells stably expressing hfa-tagged Vpr proteins (or
control cells), or transiently transfectedHEK293T cells as described
Fig. 4. Effects of mutations on Vpr abilities to arrest cells in the G2 phase,
bind VprBP and DDB1, and elevate Cul4 neddylation. (A) Mutations disrupt
the ability of Vpr to arrest cells in G2. U2OS cells were transduced with
retroviral vectors expressing wild type (HIV-1 Vpr), the indicated mutant forms
of HIV-1 Vpr, or a control empty vector (mock). Two days later, cells were
labeled with BrdU, and their cell cycle profiles were analyzed by flow cytom-
etry. (Left) Quantification of cells in the G1, S, and G2/M phases is shown. Cells
with 4N DNA content are boxed. (Right) DNA content histograms also are
shown. (B) Vpr mutations disrupt binding to DDB1 and VprBP. FLAG-tagged
wild-type and mutant HIV-1 Vpr proteins were immunoprecipitated from
transiently transfected HEK293T cells, and immune complexes were analyzed
by immunoblotting for VprBP, DDB1, and Vpr. (C) Vpr mutants unable to arrest
cells in G2 do not increase Cul4 neddylation. Wild-type and mutant HIV-1 Vpr
proteins were transiently coexpressed with myc-Cul4A and VprBP in HEK293T
cells, as described in the legend for Fig. 2A. Detergent extracts were immu-
noblotted for Cul4A and its neddylated form with -myc antibody.
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previously (45). MudPIT analysis of protein complexes was per-
formed as previously described (48, 49) and is described in detail in
SI Text. Normalized spectral abundance factors were calculated for
each detected protein as described (50).
Flow-Cytometry Analysis. To visualize cells in S phase, cells were
labeled with BrdU for 30 to 60 min. BrdU was detected with
APC-conjugated -BrdU antibody (Becton Dickinson, San Jose,
CA) and DNA counterstained with 0.1 mg/ml propidium iodide
(PI). For DNA content analysis only, cells were fixed with
ethanol, and DNA was then stained with PI. The cells were
analyzed on a Becton Dickinson LSRII Flow Cytometer, and
data were processed with FlowJo software.
Transient Transfections, Immunoprecipitations, and Immunoblotting.
Detergent extracts from transiently transfected HEK293T cells
were immunoprecipitated with -FLAGM2 affinity gel (Sigma–
Aldrich, St. Louis, MO) (45). For preparation of lysates, U2OS
cells were harvested by trypsinization, washed with PBS, and
boiled in five volumes of Laemmli sample loading buffer.
Antibodies used for immunoblot analyses are listed in SI Text.
Fluorescent Microscopy. U2OS cells grown on coverslips were
fixed in 2% paraformaldehyde in PBS for 15 min and perme-
abilized with 0.5% Triton X in PBS for 5 min on ice. Incubations
with primary and secondary antibodies were performed as
described (46). Cells were counterstained with 0.5 g/ml DAPI
(Sigma–Aldrich). Slides were imaged with a Zeiss Axioplan2 or
iCys laser scanning cytometer (Carl Zeiss, Thornwood, NY).
In Vitro Ubiquitin Ligase Activity Assay. To measure ubiquitin ligase
activity, Cul4–DDB1[VprBP] complexes assembled in the absence
or presence of HIV-1 NL43Vpr expression inHEK293T cells were
purified by immunoprecipitation via their FLAG-VprBP subunits
and incubated at 30°C for 60 min with 0.2 g of UbaI E1, 0.03 g
of UbcH5b, 5 g of ubiquitin (BIOMOL Research Laboratories,
Plymouth Meeting, PA) in the medium of 50 mM TrisHCl (pH
8.0), 5 mM MgCl2, 0.2 mM CaCl2, 1 mM DTT.
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